We then hypothesized whether BCLAF1 affects the efficacy of ICB therapy, which is important for the introduction of BCLAF1 as a potential therapeutic target for enhanced ICB therapy in HCC. The gene discussed is BCLAF1; the disease is hepatocellular carcinoma.